Nina W. Zhao

Nina W. Zhao

Auto-generated profile, based on publicly available information

Nina W. Zhao

Case Western Reserve University School of Medicine, Cleveland, Ohio; Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Cleveland, Ohio

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2013 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
PDF file
NANithin D. Adappa
Nithin D. Adappa
ZZZi Zhang
Zi Zhang
JPJames N. Palmer
James N. Palmer
DKDavid W. Kennedy
David W. Kennedy
LDLaurel Doghramji
Laurel Doghramji
NCNoam A. Cohen
Noam A. Cohen

15 December 2008 in Cancer Research
Verified
Journal Article
Open access
PDF file
GDGirish C. Daginakatte
Girish C. Daginakatte
SGScott M. Gianino
Scott M. Gianino
NZNina W. Zhao
Nina W. Zhao
APAlexander S. Parsadanian
Alexander S. Parsadanian
DGDavid H. Gutmann
David H. Gutmann
Neurofibromatosis-1 (NF1) is a common tumor predisposition syndrome in which affected individuals develop benign and malignant tumors. Previous studies from our laboratory and others have shown that benign tumor formation in Nf1 genetically engineered mice (GEM) requires a permissive tumor microenvironment. In the central nervous system, Nf1 loss in glia is insufficient for glioma formation unless coupled with Nf1 heterozygosity in the brain. Our subsequent studies identified Nf1+/− microglia as a critical cellular determinant of optic glioma growth in Nf1 GEM. Using NF1 as an experimental paradigm to further characterize the role of microglia in glioma growth, we first examined the properties of Nf1+/− microglia in vitro and in vivo. Nf1+/− microglia exhibit increased proliferation and motility and express elevated levels of genes associated with microglia activation. We further show that Nf1+/− microglia harbor high levels of activated c-Jun-NH2-kinase (JNK) without any significant changes in Akt, mitogen-activated protein kinase (MAPK), or p38-MAPK activity. In contrast, Nf1−/− astrocytes do not exhibit increased JNK activation. SP600125 inhibition of JNK activity in Nf1+/− microglia results in amelioration of the increased proliferation and motility phenotypes and reduces the levels of expression of activated microglia-associated transcripts. Moreover, SP600125 treatment of Nf1 optic glioma–bearing GEM results in reduced optic glioma proliferation in vivo. Collectively, these findings suggest that Nf1+/− microglia represent a good model system to study the role of specialized microglia in brain tumorigenesis and identify a unique Nf1 deregulated pathway for therapeutic studies aimed at abrogating microenvironmental signals that promote brain tumor growth. [Cancer Res 2008;68(24):10358–66]

1 February 2013 in Resuscitation
Verified
Journal Article
Closed access
JBJustin C. Bosley
Justin C. Bosley
NZNina W. Zhao
Nina W. Zhao
SHShawndra Hill
Shawndra Hill
FSFrances S. Shofer
Frances S. Shofer
DADavid A. Asch
David A. Asch
RMRaina M. Merchant
Raina M. Merchant

1 July 2016 in American Journal of Rhinology & Allergy
Verified
Journal Article
Closed access
RCRaewynn G. Campbell
Raewynn G. Campbell
DFDouglas Farquhar
Douglas Farquhar
NZNina Zhao
Nina Zhao
ACAlexander G. Chiu
Alexander G. Chiu
NANithin D. Adappa
Nithin D. Adappa
JPJames N. Palmer
James N. Palmer
Background: Endoscopic endonasal repair of cerebrospinal fluid (CSF) rhinorrhea secondary to idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri or benign intracranial hypertension, has varying success rates, from 25–87%, with minimal morbidity. However, often these series have a relatively short-term follow-up. Given the pathophysiology of IIH, long-term follow-up is necessary to identify true CSF leak recurrence rates. Our investigation aimed to evaluate long-term outcomes in endoscopically repaired CSF leaks. Methods: A retrospective chart review of all the patients with CSF rhinorrhea due to IIH who met inclusion criteria between 1996 and 2009. Outcome measures included the following: demographics, intracranial pressure, location of skull base defect, presence of encephalocele and/or meningoencephalocele, surgical repair technique, treatment with acetazolamide, whether a ventriculoperitoneal shunt was inserted, location of recurrence, history of meningitis or previous sinus surgery, and duration of follow-up. Results: Thirty-two patients with a total of 44 skull base defects were reviewed over a mean follow-up of 10.2 years. The mean body mass index and intracranial pressure were 36.8 kg/m 2 and 27.7 cm H 2 O, respectively. Seven patients (18%) required revision surgery at the same site or a distant site. We found no statistical significance that identified the recurrence risk in the outcome measurements most likely due to our small failure rate. However, early recurrences were noted to recur at the same repair site, whereas late recurrences were noted to recur at a distant site along the skull base. Conclusion: IIH is an increasingly recognized entity treated by otorhinolaryngologists. We present the first long-term IIH CSF leak repair series. Long-term follow-up is necessary because delayed CSF leaks occur in this population.

1 August 2019 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
NZNina W. Zhao
Nina W. Zhao
DCDylan K. Chan
Dylan K. Chan

29 August 2022 in The Laryngoscope
Verified
Journal Article
Closed access
NZNina W. Zhao
Nina W. Zhao
JMJames M. Mason
James M. Mason
ABAlexander M. Blum
Alexander M. Blum
EKEric K. Kim
Eric K. Kim
VYVyVy N. Young
VyVy N. Young
SSSarah L. Schneider
Sarah L. Schneider